Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



From the monthly archives: December, 2016

We are pleased to present below all posts archived in 'December, 2016'. If you still can't find what you are looking for, try using the search box.

Oxford Immunotec to Present at the 35th Annual J.P. Morgan Healthcare Conference

21 December 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017, at 4:00 p.m. PST (7:00 p.m. EST) at the Westin St. Francis on Union Square in San Francisco, CA.

A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 60 days.

Call for Proof of Concept Proposals

19 December 2016: Didcot, UK - In collaboration with the Harwell HealthTec Cluster.  Proposals are invited for collaborative projects between Industry and members of the Harwell HealthTec Cluster, together with Universities where appropriate. The call is for project definition and proof of concept activities in the Life Sciences and Healthcare arenas that would position the project teams to bid for larger funding opportunities within other programmes and thereby to accelerate the pace of innovation in this area. This call is specifically designed to stimulate industrial engagement with the new HealthTec Cluster at Harwell and kick-start innovative cross-sector collaborations e.g. between medicine and Space, lasers, big data etc. We are very open to new ideas on innovative use of technologies, new applications and processes. Particular themes of interest include environmental exposure and human diseases, ageing, and drug discovery. Proposals to work with more than one Cluster organisation are particula ...

Read the rest of entry »

The BioHub Birmingham® Hosts National Life Science Event: BioBrum – 16th February 2017

15 December 2016: Birmingham, UK - The BioHub Birmingham®, Birmingham’s flagship life science incubator, is hosting its first BioBrum Life Science event on 16th February 2017.  Aimed at pre-revenue life science companies the free event will include talks on finance, intellectual property, effective use of professional networks and business development.  There will also be an opportunity for one-to-one advice sessions with IP, finance and business planning specialists.

Read the rest of entry »

Charnwood Molecular Appoints New Head of Medicinal Chemistry

14 December 2016: Loughborough, UK - CRO, Charnwood Molecular Ltd, appoints Dr James Hitchin as its new Head of Medicinal Chemistry to lead its research services laboratories at BioCity, Nottingham. Dr Hitchin brings extensive experience from across multiple therapeutic areas in drug discovery to the Charnwood team.  James has previously held positions at SAFC Pharma, Pfizer Pharmaceuticals and KemFine Oy.  Most recently he was Senior Medicinal Chemist at the Cancer Research UK Manchester Institute, where he worked on various target classes, including kinases and epigenetic targets from hit identification right through to lead optimization and beyond. “I am looking forward to the challenge of leading Charnwood Molecular’s Medicinal Chemistry division”, states James. “We are experiencing significant growth in our chemistry services business, including an increase in demand for the medicinal chemistry research that we undertake at the BioCity laboratories. Charnwood&rsquo ...

Read the rest of entry »

PiR looks forward to another successful year of growth in 2017

13 December 2012: St Ives, UK - 2016 has proven to be a phenomenal year of success and growth for the specialist life science recruitment company PiR. Team work, client engagement and an in-depth understanding of the market have resulted in PiR’s most exciting and rewarding year to date, as it continues to work with an outstanding array of early-stage, investor-backed life science organisations. The boutique company made several new appointments during 2016, including a client services manager for the interims business, a project administrator and a trainee researcher. Significant promotions have also taken place; Sally Hope is now CEO and Nicola Williams continues to provide the critical back office glue in her new role as Business Operations Director. The growth and development of the team has helped to underpin both the executive search practice, specifically for innovative companies in the gene and cell therapy arenas, and the interims practice, where PiR continues to extend its reach to a sought ...

Read the rest of entry »

AMSBIO Introduces the MitoXpress® Xtra Fatty Acid Oxidation Kit 

13 December 2016: Abingdon, UK - AMSBIO has introduced the MitoXpress® Xtra Fatty Acid Oxidation (FAO) kit to facilitate the convenient measurement of FAO-driven respiration. Fatty acid oxidation is the primary metabolic pathway in a variety of tissues, which is particularly important during periods of glucose deprivation. In organs such as liver and skeletal muscle, FAO can provide over 75% of cellular ATP while in cardiac tissue it can be responsible for up to 90% of cellular energy requirements. FAO is today also acknowledged as a key factor in cancer metabolism and is also implicated in drug-induced microsteatosis. The MitoXpress® Xtra FAO kit is designed for use with the MitoXpress® Xtra HS - Oxygen Consumption Assay and contains the 18C unsaturated fatty acid Oleate as substrate, supplied as a 2:1 BSA conjugate. The kit also contains a buffer tablet and L-Carnitine for convenient preparation of measurement media and two FAO modulators, Etomoxir and FCCP. AMSBIO's MitoXpress® ...

Read the rest of entry »

Oxford Nanopore Announces £100M Fundraising

12 December 2016, Oxford, UK - Oxford Nanopore Technologies Ltd, the UK-based technology company that has designed and sells the world’s only portable DNA/RNA sequencer, has raised £100 million ($126 million) in new funding through a private placement of ordinary shares. The investment round was led by new investor GT Healthcare Capital Partners ("GT Healthcare"), a pan-Asian fund with special reach in China, as well as existing investor Woodford Investment Management on behalf of its clients.  Other new and existing investors including IP Group plc also participated in the round.

Read the rest of entry »

Oxford Sciences Innovation Announces £230m Fundraising

09 December 2016: Oxford, UK - Oxford Sciences Innovation announces a substantial increase of capital raised worldwide to scale innovative ideas from the University of Oxford into world class companies. OSI’s capital base stood previously at £350m, but a fresh injection of capital will now boost this to almost £600m. Some of Asia’s leading technology companies and sovereign wealth funds, as well as European industrialists, are among the wave of new investors.

Read the rest of entry »

Oxford Immunotec Announces New England Journal of Medicine Publication on Clinical Trial Results of Serological and Nucleic Acid Tests for Babesia in Blood Screening

08 December 2016: Oxford, UK & Marlborough, USA - Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that the New England Journal of Medicine (“NEJM”) has published an article on a three-year clinical trial completed by Oxford Immunotec’s Imugen division, and the American Red Cross (“ARC”) to evaluate a serology and Nucleic acid Amplification Test (“NAT”) testing regime for Babesia in blood screening. The review article “Screening for Babesia microti in the US blood supply” is authored by Susan Stramer of the American Red Cross, and will appear in the December 8, 2016 print issue. Babesia, or babesia microti, is a parasitic protozoan transmitted by ticks and is particularly prevalent in the Northeastern part of the US. It infects red blood cells and can cause a di ...

Read the rest of entry »

Oxford City Council Approves New Building at The Oxford Science Park

07 December 2016: Oxford, UK - The Oxford Science Park is delighted that Oxford City Council has passed a resolution to approve its detailed planning application for a new state of the art office building, with roof terrace, comprising 61,500 sq ft (5,713 sq m), and capable of accommodating 500 employees.

Read the rest of entry »

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

Future Blends are looking for an OBN member company who could help them strip solvent from one of their process streams. Initially looking at a 1 tonne scale. If you can help, or know of someone who might be able to then please contact Shane O’Leary at Future Blends. soleary@futureblends.com.

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.